Roman Shrestha1,2, Frederick L Altice2,3,4, Michael M Copenhaver1,2. 1. Department of Allied Health Sciences, University of Connecticut, Storrs, CT. 2. Institute for Collaboration on Health, Intervention, and Policy, University of Connecticut, Storrs, CT. 3. Department of Internal Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT. 4. Division of Epidemiology of Microbial Diseases, Yale University School of Public Health, New Haven, CT.
Abstract
BACKGROUND: Opioid agonist therapies with methadone are associated with higher levels of adherence to antiretroviral therapy (ART); yet, no studies have explored factors associated with optimal ART levels in HIV-positive patients on methadone maintenance treatment, including explanatory pathways using mediation analysis. SETTING:Participants included 121 HIV-positive, methadone-maintained patients who reported HIV-risk behaviors and were taking ART. METHODS: Participants were assessed using an audio computer-assisted self-interview. Multivariable logistic regression was used to identify significant correlates and PROCESS macro to test the explanatory pathway (ie, mediational effect) for optimal ART adherence. RESULTS: Among 121 participants, almost 40% reported suboptimal adherence to ART. Optimal ART adherence was significantly associated with being virally suppressed [adjusted odds ratio (aOR) = 6.470, P = 0.038], higher motivation to adhere to ART (aOR = 1.171, P = 0.011), and lower anticipated HIV-related stigma (aOR = 0.384, P = 0.015). Furthermore, results revealed an indirect effect of motivation on the relationship between HIV stigma and ART adherence (effect = -0.121, P = 0.043), thus supporting the mediation effect. CONCLUSIONS: Our findings underscore the complexities surrounding ART adherence, even in patients on methadone maintenance treatment. These findings provide insights on how to more effectively intervene to optimize HIV treatment outcomes, including HIV treatment-as-prevention initiatives, in methadone-maintained patients.
RCT Entities:
BACKGROUND: Opioid agonist therapies with methadone are associated with higher levels of adherence to antiretroviral therapy (ART); yet, no studies have explored factors associated with optimal ART levels in HIV-positive patients on methadone maintenance treatment, including explanatory pathways using mediation analysis. SETTING:Participants included 121 HIV-positive, methadone-maintained patients who reported HIV-risk behaviors and were taking ART. METHODS:Participants were assessed using an audio computer-assisted self-interview. Multivariable logistic regression was used to identify significant correlates and PROCESS macro to test the explanatory pathway (ie, mediational effect) for optimal ART adherence. RESULTS: Among 121 participants, almost 40% reported suboptimal adherence to ART. Optimal ART adherence was significantly associated with being virally suppressed [adjusted odds ratio (aOR) = 6.470, P = 0.038], higher motivation to adhere to ART (aOR = 1.171, P = 0.011), and lower anticipated HIV-related stigma (aOR = 0.384, P = 0.015). Furthermore, results revealed an indirect effect of motivation on the relationship between HIV stigma and ART adherence (effect = -0.121, P = 0.043), thus supporting the mediation effect. CONCLUSIONS: Our findings underscore the complexities surrounding ART adherence, even in patients on methadone maintenance treatment. These findings provide insights on how to more effectively intervene to optimize HIV treatment outcomes, including HIV treatment-as-prevention initiatives, in methadone-maintained patients.
Authors: Bulent Turan; Abigail M Hatcher; Sheri D Weiser; Mallory O Johnson; Whitney S Rice; Janet M Turan Journal: Am J Public Health Date: 2017-04-20 Impact factor: 9.308
Authors: Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming Journal: N Engl J Med Date: 2011-07-18 Impact factor: 91.245
Authors: Robert Gross; Benita Yip; Vincent Lo Re; Evan Wood; Christopher S Alexander; P Richard Harrigan; David R Bangsberg; Julio S G Montaner; Robert S Hogg Journal: J Infect Dis Date: 2006-09-12 Impact factor: 5.226
Authors: Shoshana Y Kahana; Maria Isabel Fernandez; Patrick A Wilson; Jose A Bauermeister; Sonia Lee; Craig M Wilson; Lisa B Hightow-Weidman Journal: J Acquir Immune Defic Syndr Date: 2015-02-01 Impact factor: 3.731
Authors: James M McMahon; Amy Braksmajer; Chen Zhang; Natalie Leblanc; Michael Chen; Angela Aidala; Janie Simmons Journal: AIDS Res Ther Date: 2019-11-09 Impact factor: 2.250
Authors: Lam Van Nguyen; Thao N P Nguyen; Anh N Thach; Anh N Lam; Duc Q Lam; Chu X Duong; Suol T Pham; Thao H Nguyen; Dyah A Perwitasari; Katja Taxis; Phuong M Nguyen; Thang Nguyen Journal: Healthcare (Basel) Date: 2021-04-20
Authors: Patricia de Los Rios; Chinyere Okoli; Erika Castellanos; Brent Allan; Benjamin Young; Garry Brough; Marvelous Muchenje; Anton Eremin; Giulio Maria Corbelli; Marta McBritton; W David Hardy; Nicolas Van de Velde Journal: AIDS Behav Date: 2020-10-07